Jiang, Tingting
Henderson, Jordana M.
Coote, Kevin
Cheng, Yi
Valley, Hillary C.
Zhang, Xiao-Ou http://orcid.org/0000-0002-2027-1313
Wang, Qin http://orcid.org/0000-0003-1991-5246
Rhym, Luke H.
Cao, Yueying
Newby, Gregory A.
Bihler, Hermann http://orcid.org/0000-0002-8167-1548
Mense, Martin http://orcid.org/0000-0003-0280-9789
Weng, Zhiping
Anderson, Daniel G. http://orcid.org/0000-0001-5629-4798
McCaffrey, Anton P.
Liu, David R.
Xue, Wen http://orcid.org/0000-0002-9797-8042
Funding for this research was provided by:
American Cancer Society (129056-RSG-16-093)
Cystic Fibrosis Foundation
Article History
Received: 2 December 2019
Accepted: 2 April 2020
First Online: 24 April 2020
Competing interests
: D.R.L. is a consultant and co-founder of Editas Medicine, Pairwise Plants, Prime Medicine, and Beam Therapeutics, companies that use genome editing. W.X. is a consultant for the Cystic Fibrosis Foundation Therapeutics Lab. The other authors declare no competing interests.